Docstoc

슬라이드 1 - PDF

Document Sample
슬라이드 1 - PDF Powered By Docstoc
					                                                                                                                                                               GCC

 Green Cross Corp.
Summary                   Company Overview

Partnering Interests:     Green Cross Corporation (GCC) is one of the leading research based biomedical and pharmaceutical
                          companies in Korea. The corporate headquarter and R&D facilities are located Yongin. GCC has 4
Co-development and
                          production plants including newly built vaccine production plant in Hwasun and biologics production
Marketing
                          plant in Ochang. Since its establishment in 1967, GCC has pioneered in the field of
                          biopharmaceuticals, such as vaccines, plasma-derivatives, diagnostics, recombinant proteins and
                          therapeutic antibodies.

                          Historically, GCC has been well known for the R&D and commercialization of ‘Hepavax B’, a
                          world's biggest selling hepatitis B vaccine, ‘Hantavax’, a world’s first epidemic hemorrhagic fever
                          vaccine, and ‘Suduvax’, a world’s second chicken pox vaccine. Starting from the nation’s first
                          Albumin production in 1971, it currently manufactures more than 12 plasma fractions including
                          immunoglobulins, antihemophilic factors, and antithrombin factor. Manufacturing over 250
                          diagnostic reagents in 41 items, GCC is the leader in the nation’s diagnostic reagent sector. Recent
                          innovations include ‘BDD rhFVIII (Greengene)’, a recombinant human coagulant factor VIII.

                          With continuous investment in R&D, its portfolio now includes gene/cell therapeutics and small
                          molecule drugs. In 2008, GCC earned $516.1 million in revenue recording it as Korea’s fifth
                          pharmaceutical company and invested $41.5 million in R&D which is one of the biggest in Korea.



                          Opportunity Highlights

                          GCC focuses its research effort on basic and applied science in oncology, infectious diseases
                          (vaccines and therapeutics), genetic blood disorder, inflammatory diseases, and CNS diseases.
                          Of those therapeutic areas, most of the GCC’s current portfolio can be grouped into development of
                          vaccines, therapeutic proteins (recombinant proteins and antibodies), and small molecules.
                          GCC aim to expand its presence in the global market through collaborations and out-licensing while
                          seeking to collaborate or acquire products and technologies to strengthen our pipeline and the R&D
                          capability.



                        GCC R&D Pipeline 2009
                                                                        Ph   Ph    Ph                                                                   Di s e a s e
                               P roje c t               D   NC   I ND                    NDA       A         M            In dic a t i on
Interested in this                                                       I    II   III                                                                  c ate gory
technology?                          G CF LU T M                                                                 Flu
Ask for more                          Anthrax                                                                    Anth rax                               In fe c t ion ,
information.                        T d (a d u l t )                                                             Te tanu s , diph te ria                onc ology

                                                 AI                                          V accine            P r e -p a n d e mi c f l u
Contact:                BDD r h F a c t o r V I I I
                                    ( G r een G en e)
                                                                                                                 He mo p h i l i a A
Tel: +82 31 260 9361
                                         rhPTH                                                                   O s te oporos is                       On c ology ,
Fax: +82 31 260 9408
                            r h a n t i -HBs A g                                                                 HBV                                 i n f l a mma t i o n ,
                                                                                                                                                    b l o o d /g e n e t i c ,
                                 P E G -G CS F                                                                   Gra nu loc y tope nia                    in fe c t ion
E-mail:
                                          r h LK8                                                                A n t i -a n g i o g e n e s i s
kim.younghwa                              r h I DS                                            P rote in          Hu n t e r s y n d r o me
@greencross.com                                                                               S ma l l           P a r k i n s o n 's
                                   G CC1290K                                                                                                                 CNS
                                                                                            mo l e c u l e       dis e as e
                                                                                             Na t u r a l
                                 S i n b a r o Ex                                                                Arthritis
Web:                                                                                        produ c t                                                   On c ology ,
                                 NK t h e r a p y                                         Ce l l t h e r a p y   Ca n c e r                          i n f l a mma t i o n ,
www.greencross. com                                                                                                                                       in fe c t ion
                                    DT C-A p o                                           s i R NA d e l i v e r y HBV /HCV

      Green Cross Corporation                                                                  303 Bojeong-dong, Giheung-gu, Yongin, 446-770, Korea
     GC1101                                                                                                                                                                                                GCC

 BDD rhFVIII A/F
 Albumin-      B-
 Albumin-free, B-domain deleted recombinant human coagulation factor VIII


Summary                  Introduction
                         Hemophilia A is a X- linked genetic disorder that affects 1-2 individuals per 10,000 males. It is
Indication:              caused by deficiency for or structural abnormality of blood coagulation factor VIII (FVIII). The
                         human plasma-derived coagulation FVIII, which has been used as a conventional therapeutic agent, is
Hemophilia A
                         effective but considered to carry a risk of contaminations with blood-borne pathogens such as HIV
                         and hepatitis viruses.
Development Stage:       To overcome the safety concern, we have produced BDD rhFVIII (Greengene, B-domain deleted
NDA filing scheduled     recombinant human coagulation FVIII) using a mammalian cell culture system (approved by Korea-
for 2010                 FDA in 2008). We are currently developing BDD rhFVIII A/F (GC1101, albumin-free BDD rhFVIII)
                         with advanced virus clearance and inactivation processes to improve safety even further.
Intellectual Property:
                         Development Summary
KR 251286
                         • GC1101 is produced by a CHO-DG44 line.
KR 254574A
KR 624013                • An optimized expression and secretion condition with low proteolytic degradation is established.
US 6,887,852             • Albumin-free and animal source-free culture, purification and formulation processes are developed.
                         • Advanced virus inactivation and clearance (nanofiltration) processes are adapted.
Partnering Interests:    • Working cell bank and manufacturing cell bank are established and validated.
Co-development and       • Manufacturing processes are in comply with GMP regulation.
Marketing                • NDA filing is scheduled for 2010.


                           Homogeneity of GC1101                                  In vivo efficacy of FVIII                                                                          Stability of GC1101
                                                                                        in KO mouse
                                A   B   C   D       E                                                                                                                                                      Greengene
                                                                                                Wild type                                                                                                  GC1101
                                                                                                FVIII-KO mouse                                                                100
                          97
                                                                        100
                                                                                                                                                                              80
                           66                                           80
                                                                                                                                                         A c ti v i ty (% )




                                                                                                                                                                              60
                                                              % FVIII




                                                                        60

                           45                                                                                                                                                 40
                                                                        40

                                                                                                                                                                              20
                                                                        20

                                                                                                                                                                               0
                                                                         0                                                                                                          0M    1M    3M     6M       18M
                                                                                            d                 d                 III                III
                         A. Molecular marker (Kd)                                         te                te                FV                 FV                                            Month
                                                                                    r   ea            r   ea              a                    rh
                         B. BDD rhFVIII (Competitor)                              nt                nt                m                    D
                                                                              U                 U                   as                BD
Interested in this       C. Thrombin-treated BDD rhFVIIIa (Competitor)                                            Pl

technology?              D. GC1101
                         E. Thrombin-treated GC1101
Ask for more             Reference: Figure for lane A~C is from
information.             Sandberg et al., 2001 Seminars in
                         Hematology, Vol38, No 2, pb 4-12


Contact:
Tel: +82 31 260 9361     Potential Benefits
Fax: +82 31 260 9408     • Improved safety using animal source-free and albumin-free processes and formulation.
                         • B-domain deletion improved homogeneity and stability over full-length FVIII without loosing
E-mail:                    activity
kim.younghwa             • Improved purity and reduced proteolytic degradation enabled by using an in-house developed
@greencross.com            monoclonal antibody for immuno-affinity purification
                         • The higher concentration enables more convenient administration (injection volume is reduced from
Web:                       10 ml to 4 ml)
www.greencross. com

      Green Cross Corporation                                                                                                   303 Bojeong-dong, Giheung-gu, Yongin, 446-770, Korea
     MG1101                                                                                                                            GCC

  rhPTH
                                Hormone(1-
  Recombinant Human Parathyroid Hormone(1-84)


Summary                   Introduction
                          PTH (parathyroid hormone) is a peptide of 84 amino acid residues that is synthesized in and secreted
Indication:               from the parathyroid gland. It is a major regulator of calcium and skeletal homeostasis, acting
Osteoporosis              primarily through its receptor on target cells in bone and kidney. Unlike its physiological role as a
                          catabolic molecule, the intermittent administration of PTH mediates anabolic increase of bone mass
Development Stage:        as has been demonstrated in clinical studies. This unusual property of PTH is being exploited and
                          several drugs have been launched.
Phase I and II clinical
studies were completed    PTH, as a therapy for osteoporosis, is unique in that it is anabolic in bone, as compared to currently
in US, UK and             available therapies such as estrogen, calcitonin and bisphosphonates which are all anti-resorptives.
Germany.
                          Development Summary
Intellectual Property:    •E.coli based large-scale expression and process system for MG1101 is established.
• KR700869                •Pre-clinical efficacy and toxicity studies are completed in mouse, rat and cynomolgus monkey.
  (PCT/KR06/02167)        •Phase IA clinical study is completed in the UK
• KR255270                         Healthy volunteers
• KR230578                         Single-blinded
  (PCT/KR98/00146)                 Dose escalating
• KR180804                •Phase IB study is completed in the USA
• KR166424                         Healthy postmenopausal women.
• KR165593                         Randomized
                                   Double-blinded
Partnering Interests:              Multi-dosing (daily dosing for 7 days)
Co-development &          •A phase II study is completed in Germany
marketing                          200 patients with postmenopausal osteoporosis
                                   Randomized
                                   Double-blinded
                          •MG1101was well tolerated and the primary endpoint result (intra-individual percentage change of the
                          bone mineral density of the lumbar spine L2-L4, DXA-method) demonstrated a statistically significant
                          increase of bone marrow density in the patients treated with medium (75 μg) and high (100 μg) dose of
                          MG1101 (6.4% and 7.5% respectively) as compared to the patients treated with low (50 μg) dose of
                          MG1101 or placebo (3.4% and 1.5% respectively).




Interested in this
technology?                                              high dosage
                                                    8    medium dosage
Ask for more
                                                         low dosage
information.                                        7
                                                         placebo
                                 Mean change in %




                                                    6
Contact:                                            5
Tel: +82 31 260 9826                                4
Fax: +82 31 260 9870                                3
                                                                                                   Fig. Phase II study result of MG1101.
                                                    2
                                                                                                   Time course of intra-individual percentage
Email:                                                                                             change of BMD in the lumbar spine (L2-
                                                    1
kim.younghwa                                                                                       L4), per protocol population.
                                                    0
@greencross.com                                         Baseline   Visit 5   Final Visit


Web:
www.greencross.com

      Green Cross Corporation                                                              303 Bojeong-dong, Giheung-gu, Yongin, 446-770, Korea
     GC1102                                                                                                                                 GCC

  rh anti-HBsAg
  A Fully Human mAb that Neutralizes Hepatitis B Virus


Summary                   Introduction
                          Hepatitis B virus (HBV) is one of the main pathogens responsible for hepatitis and hepatocellular
Indication:               carcinoma. Human plasma-derived Hepatitis B immunoglobulin (HBIG) has effectively been used to
Liver transplantation,    prevent infection following exposure to the virus (e.g. infants exposed to HBV positive mother) and
prophylaxis of HBV,       hepatitis B recurrence following liver transplantation. However, to overcome the high cost and safety
and chronic hepatitis B   concerns related to the plasma derived product and to improve efficacy, it became necessary to
treatment                 develop a recombinant anti-hepatitis B antibody. GC1102 is a recombinant human HBV- neutralizing
                          antibody that recognizes the conformational ‘a’ determinant of HBsAg.
Development Stage:
Phase II/III clinical     Development Summary
studies in KR             • GC1102 is produced in a CHO-DG44 cell line.
                          • GC1102 binds specifically to HBV-infected human liver tissue but not to normal human tissues.
Intellectual Property:    • 500L scale culture, purification and analytical procedures meeting the GMP standards are
KR0467706                 established.
KR0523732                 • In vivo HBV-neutralizing effect is shown using HBV-naïve chimpanzees.
KR0635370                 • Phase I clinical trial is completed.
PCT/KR08/06866                      Open label, active control (I.V.-Hepabig Inj, a plasma-derived HBIG), ascending single dose.
PCT/KR08/06868                      I.V.(GC1102: bolus; I.V.-Hepabig Inj: infusion)
                                    Result:
Partnering Interests:               -GC1102 is well tolerated up to 8-fold higher than the clinical dose of I.V.-Hepabig Inj.
Collaborative R&D and               -GC1102 and I.V.-Hepabig Inj dosing schedule could be the same as they showed a similar
Licensing out                       PK profile at 10,000 IU, a clinical dose of I.V.-Hepabig Inj (see figure below).
                          • Phase II/III clinical trial is scheduled to start in 2009.



                                                                            Fig. PK profile in adult (10,000 IU)



                                                             5000                                                 I.V.-Hepabig   Inj

                                                                                                                  GC1102

                                                             4000
                                              Titer (IU/L)




                                                             3000


Interested in this                                           2000
technology?
Ask for more                                                 1000
information.
                                                               0
                                                                    0   1    2   3   4    5    6      7   8   9    10   11   12
Contact:
                                                                                              Weeks
Tel: +82 31 260 9361
Fax: +82 31 260 9408
                          Potential Benefits
E-mail:                   • Increased safety
kim.younghwa              • Stable supply can be achieved, independent of the availability of plasma with high anti-HBV titer.
@greencross.com           • Convenient administration of the drug (1 ml of i. v. injection of GC1102 compared to the 200 ml i. v.
                            infusion of I.V.-Hepabig Inj -which takes about 1 hr to be administered).
Web:                      • The reduced volume per unit may enable GC1102 to be used as a therapeutic protein for chronic
                            hepatitis B infection.
www.greencross. com

      Green Cross Corporation                                                                      303 Bojeong-dong, Giheung-gu, Yongin, 446-770, Korea
    MG1107                                                                                                                                                                                    MBRI

  PEG-GCSF
  Pegylated GCSF(granulocyte colony stimulating factor)


Summary                  Introduction
                         GCSF is a glycoprotein that induces the survival, proliferation and differentiation of neutrophilic
Indication:              granulocyte precursor cells and activates mature blood neutrophils.
Neutropenia caused by    Pegylated GCSF is a long acting form of GCSF used to treat neutropenia caused by chemotherapy or
cancer                   bone marrow transplantation and is given only once after each chemotherapy unlike GCSF that
                         requires daily dosing for the period between chemotherapies. MG1107 is a new pegylated GCSF
Development Stage:       made using a site-specific pegylation technology.
In Phase I

Intellectual Property:
                         Development Summary
KR0230579
                         •Site specific pegylation is achieved by two step modifications
PCT/KR2006/002841
                                   •Step 1. Free cysteine amino acid is introduced to GCSF at a specific site using a site specific
(KR0735784)
                                   mutagenesis
                                   •Step 2. The sequence modified GCSF is pegylated at the introduced free cysteine residue
Partnering Interests:              using a cysteine-specific pegylation process
Co-development and       •The sequence modified GCSF is purified from an inclusion body in E. coli and prepared via an
Licensing out            efficient refolding process.
                         •The sequence modified GCSF is stable and shows biological activity equivalent to that of the natural
                         form.
                         •The introduced cysteine is pegylated with high specificity without any side reaction and iso-form
                         generation.
                         •MG1107 exhibited in vitro activity equivalent to Filgrastim in promoting M-NFS 60 cell proliferation.
                         •The half-life of MG1107 was about 18 hrs in rat, which is 4-fold longer than that of Filgrastim and
                         similar to Neulasta® (see figures below)




                                                                       Pharmacokinetics                                                                   In vivo efficacy
                                                          (Rat, 100 μg/kg, sc injection; ELISA Assay)                                         (Rat, 100 μg/kg, sc injection; ELISA Assay)
                                                 1.8e+5                                                                                       20
                                                 1.6e+5                                                                                                                      Neulasta (Amgen), n=5
                                                                                               Neulasta(Amgen)                                                               MG1107, n=5
                                                                                                                 Neutrophil count (X103/uL)




                                                 1.4e+5                                        MG1107                                                                        Filgrastim, n=4
                                                                                                                                              15
                          Concentration(pg/mL)




                                                                                               Filgrastim                                                                    Placebo
                                                 1.2e+5

                                                 1.0e+5
                                                                                                                                              10
                                                 8.0e+4
Interested in this
                                                 6.0e+4
technology?                                                                                                                                   5
                                                 4.0e+4
Ask for more                                     2.0e+4
information.                                     0.0
                                                                                                                                              0


                                                             0    20      40      60      80       100     120                                     0        50           100           150           200
Contact:                                                               Time after Injection (hr)                                                            Time after injection(hr)
Tel: +82 31 260 9361
Fax: +82 31 260 9408

E-mail:
kim.younghwa             Competitive advantages
@greencross.com          • A site specific, novel pegylation technology is used
                         • In vivo PK/PD data and in vitro biological activity and are comparable to Neulasta®
Web:
www.mogam.re.kr

        MOGAM Biotechnology Research Institute                                                                   341 Bojeong-dong, Giheung-gu, Yongin, 446-799, Korea
    MG1102                                                                                                            MBRI

  rhLK8
                                        apolipoprotein(a)
  Recombinant human kringle domain V of apolipoprotein(a)


Summary                  Introduction
                         Lipoprotein(a) (Lp(a)) consists of an LDL-like particle and the specific apolipoprotein(a) (apo(a)),
Indication:              which is covalently bound to the apoB of the LDL-like particle. Apo(a) is mainly synthesized in the
Hormone refractory       liver and is characterized by its repetitive kringle domains. Kringle domain is a 106~114 amino acid
prostate cancer, anti-   long protein motif arranged in a triple loop structure. Of the kringle domains in apo(a), the kringle
metastasis               domain V shows a significant sequence homology with the kringle domain V of plasminogen, which
                         is reported to have a strong angiogenetic effect.
Development Stage:       MG1102 is a 86 amino-acid long recombinant human kringle domain V of apolipoprotein(a) (rhLK8)
Non-clinical / phase I   and it is produced in yeast Saccharomyces cerevisiae. Anti-angiogenetic effect of MG1102 has been
IND                      shown previously using in vitro and in vivo assays such as CAM assay (a neovascularization assay in
                         chicken embryo) and the Matrigel plug assay and anti-cancer effect has been proven using in vivo
                         cancer models.
Intellectual Property:
KR523734
KR523737                 Development Summary
PCT/KR99/00554           • MG1102 inhibits endothelial cell migration in vitro, by inhibiting the activation of focal adhesion
(KR481206)                 kinase and consequently the formation of actin stress fibers/focal adhesions.
PCT/KR04/00357           • MG1102 inhibits neovascularization in CAM assay and Matrigel plug assay.
(KR595364)               • Alone or in combination with chemotherapeutic agent, MG1102 induced a significant apoptosis of
PCT/KR05/00214             tumor-associated endothelial cells and tumor cells in the orthotopic animal models of human
(KR595864)                 prostate, colon, pancreas, kidney, and skin cancers.
PCT/KR05/00075           • MG1102 inhibits experimental pulmonary metastasis of murine melanoma cells and bone metastasis
(KR681762)                 of human prostate cancer cells.
                         • MG1102 inhibits experimental liver metastasis of human colorectal cancer cells in nude mice and
Partnering Interests:      significantly improves survival of the hosts.
Co-development and       • MG1102 improves host survival in animals bearing orthotopic human colorectal tumors in nude
(clinical trials)          mice
Licensing-out            • Expression system Saccharomyces cerevisiae is established.
                         • 350L production and purification process is established
                         • Currently in non-clinical studies for the primary indication of hormone-refractory prostate cancer




Interested in this
technology?
Ask for more
information.

Contact:
Tel: +82 31 260 9361                               Double immunofluorescence staining for CD31 (red)
Fax: +82 31 260 9408                               and TUNEL (green). Mouse prostate cancer tissues in
                                                   a mouse orthotopic model of human prostate cancer.

E-mail:
kim.younghwa             Potential Benefits
@greencross.com          • Promising candidate molecule for treatment of cancers and their metastases.
                         • No significant toxicity observed in preliminary toxicology studies.
Web:                     • MG1102 may have potential benefits for other diseases where angiogenesis plays critical roles in
www.mogam.re.kr            the disease development and/or progression (e.g. diabetic retinopathy).

        MOGAM Biotechnology Research Institute                                341 Bojeong-dong, Giheung-gu, Yongin, 446-799, Korea
     GC1111                                                                                                                                                    GCC

  rhIDS
                    iduronate-
  Recombinant human iduronate-2-sulfatase


Summary                  Introduction
                         Hunter syndrome (MPS II: Mucopolysaccharidosis II) is a genetic disorder inherited in a X-linked
Indication:              pattern. It is caused by deficiency or abnormality of the lysosomal enzyme, iduronate-2-sulfatase
Hunter Syndrome          (IDS). This enzyme is required for the degradation of specific glycosaminoglycans (GAG) and its
                         abnormality results in a harmful accumulation of the substance in cells throughout the body which
                         eventually leads to a number of severe, progressive, and life-limiting symptoms.
Development Stage:
                         Treatment of Hunter syndrome has mostly been involved in management of the symptoms and
Non-clinical
                         complications. Bone marrow graft, while it improves most symptoms associated with Hunter
                         syndrome, is a difficult procedure and it does not improve mental conditions of the Hunter syndrome
Intellectual Property:   patients. Enzyme replacement therapy (ERT) is first approved in 2006 by the US-FDA and is
                         considered to have all the advantages of the bone marrow graft without some of its drawbacks.
Partnering Interests:    GC1111 is a recombinant human iduronate-2-sulfatase produced from a mammalian cell line and is
Co-development           being developed for the enzyme replacement therapy (ERT) for the Hunter syndrome.
/Licensing out
                         Development Summary
                         • Established a CHO-DG44 cell line for the production of GC1111.
                         • Developed cost-effective production processes and analytical methods.
                         • Confirmed GC1111 uptake in vitro by normal fibroblast and cells isolated from Hunter syndrome
                           patients.
                         • Demonstrated in vivo efficacy using a IDS knock-out mouse model for MPS II (see figures below).
                         • Phase I clinical study is scheduled for 2010.


                                                                            Untreated                                GC1111-treated




                                                             400
                                                                    -3 day s
                                                             350    10 day s
                                GAG contents in urine(ug/m




                                                                    25 day s
                                                             300

                                                             250

                                                             200
Interested in this
                                                             150
technology?
                                                             100
Ask for more
                                                             50
information.
                                                              0
                                                                   WT          IDS-KO   0.5mg/kg   1mg/kg   2mg/kg
Contact:                                                                saline                     GC1111

Tel: +82 31 260 9361
                                                                        Fig. Urine and Tissue GAG level in a knock-out mouse model of MPS II
Fax: +82 31 260 9408

E-mail:
kim.younghwa             Competitive advantages
@greencross.com          • Optimized serum-free culture system without any animal source is employed.
                         • 500L scale culture condition is established.
Web:                     • Purification process for high purity and yield is established.
www.greencross. com

      Green Cross Corporation                                                                                         303 Bojeong-dong, Giheung-gu, Yongin, 446-770, Korea
                                                                                                                           GCC

  GCC1290K
                                                   anti-
  An orally available, novel neuroprotectant as an anti-Parkinsonian drug candidate


Summary                  Introduction
                         GCC1290K is a novel neuroprotectant to treat Parkinson’s disease. After oral or intravenous
Indication:              administration, GCC1290K is rapidly converted to a parent drug, 3-Hydroxymorphinan (3-HM), in
Parkinson’s Disease      liver and intestine. 3-HM is the active compound with a potent neuroprotective activity and a good
                         safety profile.
Development Stage:
Non-clinical
                         Development Summary
Intellectual Property:   • GCC1290K, unlike its parent drug 3-HM, is orally available.
PCT/IB05/51582           • Showed in vitro neuroprotective activities of GCC1290K and its active metabolite 3-HM in PC12
(KR753984)               cells differentiated into dopaminergic neurons.
                         • Showed in vivo neuroprotective activities in MPTP-treated and LPS-treated mice (See figure below)
                         and improved locomotive activities in MPTP-treated mice.
Partnering Interests:
                         • In vitro and in vivo pharmacological characterization, pharmacokinetic and metabolite studies are
Collaborative R&D and
                         finished.
Licensing out
                         • Showed promising toxicity (Full scale non-clinical genetic, single and repeated dose toxicity studies
                         have been completed).
                                    (1) NOAEL from a 4 week repeated toxicity study in rat : 600 mg/kg
                                    (2) NOAEL from a 4 week repeated toxicity study in dog : 12.5 mg/kg
                                    (3) Human equivalency dose (HED) : 472 mg for Dog, 6.7g for Rat
                                    (4) Recommended human starting dose: 47.2 mg
                         • Process chemistry is well established and production of cGMP grade GCC1290K for phase I clinical
                         trial is completed.
                         • Neuroprotective property of 3-HM is mediated by multi--functional activities including NMDA
                         receptor antagonism and activation of neurotrophic factors and SIRT1, a stress-response and
                         chromatin-silencing factor.
                         • IND application to the US-FDA is scheduled for 4Q 2009.


                                                                                                   Fig. In vivo efficacy of
                                                                                                   orally-administered
                                                                                                   GCC1290K or Ropinirole
                                                                                                   demonstrated      using    a
                                                                                                   MPTP-induced          mouse
                                                                                                   model.
                                                                                                   Tyrosin hydroxylase (TH)
                                                                                                   expression in nigra (A) and
                                                                                                   striatum (B) is evaluated by
Interested in this                                                                                 immuno-histochemsitry.
technology?                                                                                        Each value is the mean ±
Ask for more                                                                                       S.E.M. of 6 animals. *p<0.01
information.                                                                                       vs. Vehicle+Saline, ##p<0.01
                                                                                                   vs. Vehicle+MPTP (one-
                                                                                                   way ANOVA followed by
Contact:                                                                                           Fisher’s PLSD test)
Tel: +82 31 260 9850
Fax: +82 31 260 9870

E-mail:
kim.younghwa             Potential Benefits
@greencross.com          • Highly potent neuroprotective activity.
                         • Good in vivo safety profile (in mouse, rat, dog).
Web:                     • Good bioavailability (oral BA: 92 %) compared to the parent molecule (oral BA: 18 %).
www.greencross.com

      Green Cross Corporation                                                 303 Bojeong-dong, Giheung-gu, Yongin, 446-770, Korea
     MG1105                                                                                                          MBRI
 DTC-Apo
 A novel siRNA delivery technology

Summary                  Introduction
                         Applicability of small interfering RNA (siRNA) as a therapeutic molecule is dependent on the
Indication:              availability of a suitable delivery technology. Recently, we have developed a cationic lipid (DTC)-
Anti-hepatitis virus     based delivery system which enables liver-targeted transfer of siRNA safely, efficiently, and
                         selectively, via intravenous administration. Our novel technology is based on the use of apolipoprotein
Anti-cancer
                         A-I as a targeting moiety. In a HCV mouse model expressing viral structural proteins, anti-viral
                         activity of systemically treated siRNA was evaluated. It suggests that this cationic liposome DTC-Apo
Development Stage:       (MG1105) could be applicable for the development of siRNA-based drugs against hepatocellular
Clinical studies are     carcinoma as well as HCV or HBV infections.
expected to start in
2011.
                          Development Summary
                          • MG1105, self-assembled nanoparticles of DTC and apolipoprotein A-I, is shown to deliver
Intellectual Property:
                          dsDNA into liver better than DTC without apolipoprotein A-1 (see Fig 1.)
Korean patents were
                          • MG1105 complexed with siRNA againt HCV showed in vivo efficacy in a mouse HCV model (see
registered and PCT
                          Fig 2.)
applied

Partnering Interests:
Co-development and
Licensing out




                                       Fig 1. Liver-targeted delivery of nucleic acids by MG1105 in mouse

                                                     MG1105




Interested in this
technology?
Ask for more
information.                     Fig 2. MG1105/siRNA (HCV specific or scrambled) complex was injected via i.v. into
                                mice expressing HCV structural proteins (core, E1 and E2) in their hepatocytes. Anti-viral
Contact:                        effect was determined by measuring the level of viral core expression in the liver by
Tel: +82 31 260 9852            Western blot analysis.
Fax: +82 31 260 9870
                         Current status
Email:                   • Delivery mechanism of MG1105 is being studied: A specific interaction between apolipoprotein A-I
kim.younghwa             and its cell surface receptor SR-BI is being investigated using a mouse model.
@greencross.com          • Preclinical study for HCV-specific siRNAs complexed with MG1105 will be carried out using an
                         HCV-infected animal model.
Web:
www.mogam.re.kr

        MOGAM Biotechnology Research Institute                               341 Bojeong-dong, Giheung-gu, Yongin, 446-799, Korea

				
DOCUMENT INFO